Overview

A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas

Status:
Completed

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

First in human, open-label, sequential dose escalation and expansion study of CPI-1205 in patients with progressive B-cell lymphomas. CPI-1205 is a small molecule inhibitor of EZH2.

Phase:

Phase 1

Details

Lead Sponsor:

Constellation Pharmaceuticals

Treatments:

(R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide